2025
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaNational Cancer DatabaseMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalImpact of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsPrimary treatment typeCox proportional hazards analysisSite of metastasisEvaluate clinical outcomesProportional hazards analysisBorderline statistical significancePT0 rateOS benefitHistological subtypesCancer DatabaseClinical stageClinical outcomesTreatment patternsCurrent therapiesInstitutional experiencePrimary outcome
2024
Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinomaReevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience
Takeda K, Cai G, Adeniran A, Sun T. Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience. American Journal Of Clinical Pathology 2024, 162: aqae077. PMID: 38916141, DOI: 10.1093/ajcp/aqae077.Peer-Reviewed Original ResearchCystic fluid cytologyFine-needle aspirationFluid cytologyAmerican College of Obstetricians and Gynecologists guidelinesSingle-institution cohortRate of malignancySurgical pathology diagnosisFNA casesGynecologists guidelinesCytological diagnosisFNA cytologyPathological diagnosisPatient demographicsInstitutional experienceSurgical pathologyOvarian cyst fluidClinical circumstancesAmerican CollegeCytologyRadiological informationMalignancyGold standardCyst fluidModerate sensitivityPotential safety concerns
2023
Utility of parathyroid hormone immunocytochemistry in fine needle aspiration diagnosis of parathyroid tissue
Sardana R, Abi‐Raad R, Adeniran A, Cai G. Utility of parathyroid hormone immunocytochemistry in fine needle aspiration diagnosis of parathyroid tissue. Cytopathology 2023, 34: 597-602. PMID: 37534757, DOI: 10.1111/cyt.13283.Peer-Reviewed Original ResearchConceptsParathyroid tissueFine-needle aspirationPTH casesClinicopathological characteristicsCytomorphological featuresThyroid lesionsThinPrep slidesFine needle aspiration diagnosisNeck soft tissuePatients' clinicopathological characteristicsNeedle aspiration diagnosisNegative predictive valueClinical suspicionStudy cohortPathology databaseRetrospective studyDiagnostic challengeDifferential diagnosisInstitutional experienceNeedle aspirationCytological diagnosisFNA casesAspiration diagnosisPredictive valueAdjunct test
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply